Guizhou Xinbang Pharmaceutical Co., Ltd. (referred to as: letter states pharmacy, stock code: 002390) is a traditional Chinese medicine GAP cultivation, drug development, pharmaceutical production and sales high-tech pharmaceutical enterprise. April 16, 2010, shares in the Shenzhen Stock Exchange, became a public company.

letter states pharmacy was established in January 1995, sixteen years ago, the company of "good faith to the letter, Chung Chi prosperous, healthy people, the development of people's livelihood" philosophy and the "good faith cooperation, innovation, pursuit of results," the core values of doing business. As of December 31, 2010, the company's total assets reached 1.125 billion yuan, registered capital of 86.8 million yuan, more than 800 employees, has been named national key agricultural industrialization leading enterprises, the National Credible units, high-tech enterprise national poverty alleviation leading enterprises, national innovation pilot enterprises, the state of modern science and technology industrial base of Chinese medicine tenth anniversary of outstanding units.

letter states the letter states pharmacy affiliated with the Far East Pharmaceutical Co., Ltd. of Guizhou, Guizhou Xinbang Pharmaceutical Co., Ltd. and Guizhou Xinbang three subsidiary of drug research and development Co., Ltd. have been built to extract Carey in planting and production base, production base and solid dosage Luodian Guiyang injection production base.

letter states the main business of proprietary pharmaceutical development, production and sales of products focused on cardiovascular and cerebrovascular class and digestive two series. Existing varieties 国药准字号 46, in which the State 4 varieties at competitive prices, medicine to protect species 4, exclusive varieties 2.

letter states pharmacy is committed to the modernization of Chinese medicine, adhere to the development of new products, new processes, new formulations for the company's strategic core, traditional Chinese medicine with modern high combination of technology, the introduction of high-tech, high-quality products. State consumer safety card Liuwei An Capsule is currently the first multi-center clinical study of all-natural gastrointestinal motility; Yixin capsule of the "Yixin capsule treatment of coronary heart disease and promotion of multi-center clinical research project" in 2008 January won the "2007 China High-tech Industry Innovation Award" award the first prize; New Drug for ginsenoside-Rd Injection has completed Phase Ⅲ clinical summary and access to medicines notice of acceptance of application for registration; Chinese medicine brain capsule, Breviscapine pills clinical trials have been completed. The company has applied for 47 patents (including 38 invention patents, design patents 8, utility model 1), the company "state consumer safety" and "the letter states," trade mark "Guizhou Province."

in the marketing system, the company drawing on international best pharmaceutical companies in marketing mode, and carefully build their own marketing system and team in the country 29 provinces, municipalities and autonomous regions established 70 offices.

in the future development path, the letter states will continue to pharmaceutical quality and efficient products and attentive service, honesty and good reputation to build and maintain. " letter states "brand image, to create greater wealth for the benefit of patients, the benefit of their homeland.